Treatment for Premature

Phase-Based Progress Estimates
University Health System, San Antonio, TX
Premature+1 More
< 18
All Sexes
What conditions do you have?

Study Summary

A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.

Eligible Conditions

  • Premature

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Premature

Study Objectives

6 Primary · 1 Secondary · Reporting Duration: Baseline to 36 weeks

Baseline to 36 weeks
Bronchopulmonary dysplasia (BDP)
Change in Protectin/Neuroprotectin
Change in biomarker Resolvin D1
Change in biomarker Resolvin E1
Change in circulating biomarker Lipoxin A4
Change in infant weigh
Fatty acid levels in plasma
Fatty acid levels in red blood cell (RBC) membranes
Late-onset sepsis (LOS)
Necrotizing enterocolitis (NEC)
Retinopathy of prematurity (ROP)

Trial Safety

Safety Progress

1 of 3

Other trials for Premature

Trial Design

1 Treatment Group

No DHA/ARA supplement
1 of 1
Active Control

328 Total Participants · 1 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

No DHA/ARA supplementNoIntervention Group · 1 Intervention: No DHA/ARA supplement · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 36 weeks
Closest Location: University Health System · San Antonio, TX
Photo of San Antonio  1Photo of San Antonio  2Photo of San Antonio  3
2007First Recorded Clinical Trial
1 TrialsResearching Premature
4 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are less than 48 hours of age at first lipid dose.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.